The main aim of this study was to understand how major driver mutations related to EGFR (L858R and/or Ex19del) affect downstream molecular networks and pathways, which would reflect disease nature and treatment outcomes in patients with lung adenocarcinoma (most abundant among NSCLC subtypes) who harbour these EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.